Cellosaurus logo
expasy logo

Cellosaurus Ishikawa (CVCL_2529)

[Text version]
Cell line name Ishikawa
Accession CVCL_2529
Resource Identification Initiative To cite this cell line use: Ishikawa (RRID:CVCL_2529)
Comments Part of: ENCODE project common cell types; tier 3.
Population: Japanese.
Doubling time: 36 hours (Note=At 9th passage), 29 hours (Note=At 40th passage), 27 hours (Note=At 50th passage) (DOI=10.1007/978-4-431-53981-0_2); 35.14 +- 2.68 hours (PubMed=23255909).
Omics: Array-based CGH.
Omics: Chromatin accessibility by ATAC-seq.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Misspelling: Ischikawaa; Note=Occasionally.
Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
Sequence variations
  • Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  • Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  • Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Ser302fs*4 (c.906delC); Zygosity=Heterozygous (PubMed=20944090).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=20944090).
  • Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
  • Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=15901131).
Disease Endometrial adenocarcinoma (NCIt: C7359)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_W441 (EIIL)CVCL_N296 (IK-6)CVCL_9996 (IK-90)
CVCL_IR24 (ISH/DDP)CVCL_6543 (Ishikawa (Heraklio) 02 ER-)CVCL_8783 (Ishikawa (London) 02 ER+)
CVCL_W420 (Ishikawa 1-A-12)CVCL_W421 (Ishikawa 1-A-9)CVCL_W422 (Ishikawa 1-C-10)
CVCL_W423 (Ishikawa 1-D-9)CVCL_W424 (Ishikawa 1-E-8)CVCL_W425 (Ishikawa 1-F-6)
CVCL_W426 (Ishikawa 1-H-6)CVCL_W427 (Ishikawa 2-B-12)CVCL_W428 (Ishikawa 2-C-3)
CVCL_W429 (Ishikawa 2-C-7)CVCL_W430 (Ishikawa 2-E-7)CVCL_W431 (Ishikawa 2-F-4)
CVCL_W432 (Ishikawa 3-D-7)CVCL_W433 (Ishikawa 3-D-9)CVCL_D199 (Ishikawa 3-H-12)
CVCL_W434 (Ishikawa 3-H-3)CVCL_W435 (Ishikawa 3-H-4)CVCL_W436 (Ishikawa 3-H-7)
Sex of cell Female
Age at sampling 39Y
Category Cancer cell line
STR profile Source(s): ECACC; PubMed=25877200

Penta D10,11
Penta E11,19

Run an STR similarity search on this cell line
Web pages http://genome.ucsc.edu/ENCODE/protocols/cell/human/Ishikawa_Crawford_protocol.pdf

Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi K.
Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors.
Nihon Sanka Fujinka Gakkai Zasshi 37:1103-1111(1985)

PubMed=10381137; DOI=10.1016/s0304-3835(98)00270-5
Ohta H., Sakamoto H., Satoh K.
In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum.
Cancer Lett. 134:111-118(1998)

PubMed=12703541; DOI=10.1111/j.1749-0774.2002.tb00105.x
Nishida M.
The Ishikawa cells from birth to the present.
Hum. Cell 15:104-117(2002)

Nishida M.
Ishikawa cells: opening of in vitro hormone research on endometrial carcinoma.
(In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.35-58; Springer; Tokyo (2003)

Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.
Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines.
Eur. J. Gynaecol. Oncol. 25:55-60(2004)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002
Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.
Pathol. Res. Pract. 201:109-115(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20218740; DOI=10.1177/153303461000900207
Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R., Zhang W.
Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.
Technol. Cancer Res. Treat. 9:179-189(2010)

PubMed=20944090; DOI=10.1126/scitranslmed.3001538
Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23255909; DOI=10.3892/ol.2012.975
Zhao S.-Z., Li G.-X., Yang L., Li L., Li H.-Y.
Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.
Oncol. Lett. 5:139-144(2013)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cell line collections (Providers) BCRJ; 0364
ECACC; 99040201
Ubigene; YC-D023
Cell line databases/resources CLO; CLO_0037163
cancercelllines; CVCL_2529
CCRID; 1101HUM-PUMC000686
Cell_Model_Passport; SIDM00038
LINCS_HMS; 50018
TOKU-E; 3966
Anatomy/cell type resources BTO; BTO:0003041
Biological sample resources BioSample; SAMN03471030
Chemistry resources ChEMBL-Cells; CHEMBL3307675
ChEMBL-Targets; CHEMBL614649
PharmacoDB; Ishikawa_667_2019
PubChem_Cell_line; CVCL_2529
Encyclopedic resources Wikidata; Q54898281
Experimental variables resources EFO; EFO_0005718
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM374972
GEO; GSM375431
GEO; GSM827370
GEO; GSM1008593
GEO; GSM1008594
GEO; GSM1669941
GEO; GSM3161714
GEO; GSM3161715
Polymorphism and mutation databases Cosmic; 713475
Cosmic; 713499
Cosmic; 809129
Cosmic; 846174
Cosmic; 1070811
Cosmic; 1152553
Cosmic; 1176597
Cosmic; 1177618
Cosmic; 1241344
Cosmic; 1622902
Cosmic; 1696753
Cosmic; 2030475
Cosmic; 2464666
Cosmic; 2646616
Cosmic; 2702440
IARC_TP53; 1112
Progenetix; CVCL_2529
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number35